{"certainAgreement":{"otherDetails":"The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The study remained open to allow subjects currently on treatment continued access to treatment with open label pazopanib."},"pointOfContact":{"organization":"Novartis Pharmaceuticals","phone":"862-778-8300","title":"Clinical Disclosure Office"}}